The Native Antigen Company
-
Life science company signs pre-let for R&D facility at Oxford Technology Park
The Native Antigen Company – a leading life science company has signed a pre-let for a new 50,000 sq ft R&D facility at the Oxford Technology Park in Kidlington.
-
Antigen company launches antibodies to further fight against COVID-19
The Native Antigen Company has announced the introduction of 10 new monoclonal antibodies recognising SARS-CoV-2, the causative agent of COVID-19.
-
Oxford-based The Native Antigen Company acquired by LGC
The Native Antigen Company, leading suppliers of high-quality infectious disease antigens and antibodies, has announced its acquisition by LGC.
-
Oxford firms collaborate to scale up COVID-19 antigen production
Two Oxford businesses – OXGENE™ and The Native Antigen Company – have formed a strategic partnership to scale-up SARS-CoV-2 (COVID-19) antigen production.